Sedation and General Anesthesia in Dentistry
Sedation Continuum · Nitrous Oxide · IV Sedation · General Anesthesia · Pharmacology
TL;DR
Dental sedation encompasses a spectrum of pharmacological techniques used to reduce patient anxiety and facilitate dental treatment — from minimal (anxiolysis) through moderate conscious sedation to deep sedation and general anaesthesia. The key principle underlying all sedation practice is the sedation continuum: any sedation technique can produce a deeper level of sedation than intended, and the practitioner must be trained and equipped to manage at least one level deeper than the intended level. General anaesthesia in dentistry involves complete loss of consciousness with loss of protective airway reflexes and requires a specialist anaesthetist.
- The sedation continuum (AAPD/ADA/ASA classification) defines four levels — minimal sedation (anxiolysis), moderate sedation (conscious sedation), deep sedation, and general anaesthesia — and a practitioner must be able to rescue from one level deeper than intended: The sedation continuum is not a series of discrete steps but a smooth spectrum — at any moment, a patient can transition from one level to the next without warning. Minimal sedation (anxiolysis): normal response to verbal stimulation; airway, ventilation, and cardiovascular function all unaffected. The patient is calm and cooperative but fully alert. Moderate sedation (conscious sedation): the traditional dental sedation target — purposeful response to verbal or light tactile stimulation; airway maintained without intervention; spontaneous ventilation adequate; cardiovascular function maintained. The patient is relaxed, comfortable, and able to respond to instruction, but may not remember the procedure (anterograde amnesia — particularly with benzodiazepines). Deep sedation: purposeful response only to repeated or painful stimulation; airway may require intervention; spontaneous ventilation may be inadequate; cardiovascular function usually maintained. This level requires anaesthetic-trained personnel. General anaesthesia: unarousable; airway requires intervention; spontaneous ventilation frequently inadequate (patient on ventilator); cardiovascular function may be impaired. The “rescue” principle: a practitioner providing minimal sedation must be trained to rescue from moderate sedation; a practitioner providing moderate sedation must be trained to rescue from deep sedation. In the UK, the Standards for Conscious Sedation in the Provision of Dental Care (2015, Faculty of Dental Surgery / Intercollegiate Advisory Committee on Sedation in Dentistry [IACSD]) define conscious sedation as a technique in which the patient has a reduced level of consciousness but retains protective reflexes and responds to verbal commands — general anaesthesia requires a separate qualified anaesthetist.
- Nitrous oxide/oxygen (relative analgesia/inhalation sedation) is the safest dental sedation technique — it is the only sedation modality where the recovery is complete before the patient leaves the surgery: Nitrous oxide (N₂O) is an odourless, colourless, non-flammable gas. It produces anxiolysis and mild analgesia through multiple mechanisms: NMDA receptor antagonism (reduces pain transmission); GABA-A receptor potentiation (anxiolysis); and possible endogenous opioid system modulation. Clinical effects begin within 1–2 minutes; offset within 3–5 minutes of stopping N₂O and administering 100% O₂ for 5 minutes (the post-sedation oxygen flush prevents diffusion hypoxia). Target concentration: typically 30–50% N₂O / 50–70% O₂ — the minimum oxygen concentration must never fall below 30% (all modern inhalation sedation equipment has a failsafe mechanism preventing delivery of <30% O₂ — the Porter Mapleson A system uses a proportioning valve). Maximum N₂O concentration used in the UK for conscious sedation is 70% (30% O₂) — beyond this, the patient is likely to be in deep sedation. Indications: anxious patients of all ages (particularly paediatric patients — gold standard paediatric sedation technique); patients with a strong gag reflex; needle-phobic patients (reduces anxiety before LA injection). Contraindications: first trimester of pregnancy (N₂O oxidises vitamin B12 → inhibits methionine synthase → disrupts DNA synthesis and folate metabolism — particular concern for organogenesis); nasal obstruction (cannot use inhalation route); pneumothorax, recent tympanoplasty, or middle ear surgery, bowel obstruction (N₂O is 34× more soluble than N₂ in blood — it enters air-containing spaces faster than N₂ leaves, causing pressure increase in enclosed spaces). Chronic occupational exposure: N₂O inactivates vitamin B12 irreversibly — prolonged occupational exposure causes peripheral neuropathy (subacute combined degeneration of the cord — identical to B12 deficiency). All sedation rooms must be scavenged (exhaust systems to remove waste gas) and N₂O levels monitored.
- Midazolam is the most widely used drug for IV conscious sedation in dentistry — its properties (water-soluble, rapid onset, anterograde amnesia, short duration, reversal by flumazenil) make it ideal for outpatient dental procedures: Midazolam (Hypnovel, Versed) is a short-acting water-soluble benzodiazepine. Mechanism: GABA-A receptor positive allosteric modulator — binding to the benzodiazepine site on the GABA-A receptor increases the frequency of chloride channel opening in response to GABA → CNS depression. Properties relevant to dental sedation: water-soluble at preparation pH (does not cause thrombophlebitis unlike diazepam); rapid onset (30–60 seconds after IV injection); anterograde amnesia (the patient does not form memories of the procedure after drug administration — highly desirable in dental sedation); relatively short duration (1–2 hours — appropriate for outpatient procedures); and reversible by flumazenil (competitive benzodiazepine antagonist). Titration technique (UK IACSD): the “rule of five” — 2mg IV bolus (1mg in the elderly); wait 90 seconds for effect; repeat in 1mg increments at 1-minute intervals until sedation endpoint is achieved (slurred speech, drooping eyelids, relaxed attitude, Verril’s sign — ptosis [drooping eyelid] = sedation endpoint); maximum dose approximately 0.07mg/kg (a typical 70kg adult = ~5mg). Do not exceed the sedation endpoint or respiratory depression will occur. Elderly, debilitated, and respiratory-compromised patients require reduced doses — halve the initial dose and titrate slowly. The patient must have a responsible adult escort and cannot drive or operate machinery for 24 hours (midazolam impairs psychomotor function and judgment beyond the period of perceived sedation — anterograde amnesia makes the patient believe they have recovered when they have not).
- Propofol is an IV anaesthetic agent used for deep sedation and general anaesthesia induction — it has a very narrow therapeutic window and is NOT suitable for conscious sedation by dentists in the UK unless specifically trained in deep sedation: Propofol (Diprivan) is a short-acting IV anaesthetic (GABA-A potentiation + NMDA antagonism + glycine receptor modulation). It produces dose-dependent CNS depression from anxiolysis → sedation → loss of consciousness. Properties: rapid onset (30–40 seconds); short duration (offset within minutes due to rapid redistribution); anti-emetic properties; does not cause anterograde amnesia at subanaesthetic doses; causes pain on injection (mitigated by lidocaine pre-injection or use of larger veins); causes respiratory depression (apnoea is common at induction doses — requires immediate airway management); causes hypotension (vasodilation + reduced cardiac output). In the UK, propofol for conscious sedation is used in a small number of specialist dental sedation centres by practitioners with specific deep sedation training. The ADA (USA) is slightly less restrictive — trained dentist anaesthesiologists may use propofol for deep sedation in appropriate settings. Propofol is not reversible — there is no antagonist. PRIS (propofol infusion syndrome) — rare but fatal complication of prolonged high-dose propofol infusion in ITU — characterised by metabolic acidosis, rhabdomyolysis, cardiac failure. Not relevant to dental use at outpatient doses.
- General anaesthesia for dental treatment carries specific risks from the intraoral surgical environment — airway management, shared airway, aspiration of blood and debris, and PONV are the key challenges: Dental general anaesthesia is used for: patients unable to cooperate under local anaesthesia (severe dental phobia; learning disability; dementia; young children with extensive caries requiring multiple extractions); patients with relevant medical conditions (allergy to local anaesthetics; uncontrolled movement disorders; severe gagging); and patients requiring extensive surgery requiring complete immobility. The intraoral environment presents unique anaesthetic challenges: (1) Shared airway — the surgeon is operating in the same space as the anaesthetist’s airway — either a nasal endotracheal tube or a reinforced oral tube is used; nasotracheal intubation is preferred for oral surgery as it leaves the mouth free; (2) Aspiration risk — blood, dental debris, bone fragments, and irrigation fluid pool in the oropharynx — a throat pack (moistened gauze placed at the back of the throat by the anaesthetist) prevents material passing into the larynx; the throat pack MUST be counted in and documented, and removed at the end of the case before extubation — retained throat packs cause postoperative airway obstruction and death; (3) Postoperative nausea and vomiting (PONV) — dental procedures (particularly extractions and sinus lifts) combined with blood swallowing produce a high PONV rate — prophylactic ondansetron (5-HT3 antagonist) and dexamethasone are routinely given; (4) Postoperative analgesia — adequate multimodal analgesia must be established before recovery from GA as the patient wakes in pain. Local anaesthetic is injected intraoperatively under GA for postoperative analgesia (pre-emptive analgesia).
Key Facts
What Is Dental Sedation?
Dental sedation is the use of pharmacological agents to reduce patient anxiety, facilitate dental treatment, and improve the quality of care — without causing loss of consciousness. It is distinct from general anaesthesia (where consciousness is deliberately abolished). Dental anxiety is extremely common — approximately 36% of the population experience dental anxiety and 12% have severe dental phobia — and it is the leading cause of delayed treatment-seeking, dental neglect, and poor oral health. Effective anxiety management is a core clinical skill for all dentists. The hierarchy of anxiety management: behaviour management (explanation, reassurance, tell-show-do); topical anaesthesia; effective local anaesthesia; anxiolytic premedication (oral benzodiazepines); inhalation sedation (nitrous oxide); IV sedation; and general anaesthesia.
Why It Matters
Boards test sedation through scenario questions: what is the appropriate monitoring for a patient receiving IV midazolam? A child is given oral midazolam and becomes unresponsive — what has happened and what is the management? A patient receiving N₂O becomes confused and uncoordinated — what concentration should be reduced to? What are the contraindications to nitrous oxide? What drug reverses benzodiazepine overdose? What are the hallmarks of general anaesthesia that distinguish it from deep sedation? These questions require knowledge of the sedation continuum, drug mechanisms, monitoring, and emergency management.
The Sedation Continuum
| Level | Responsiveness | Airway | Spontaneous Ventilation | Cardiovascular |
|---|---|---|---|---|
| Minimal sedation (anxiolysis) | Normal response to verbal stimulation | Unaffected | Unaffected | Unaffected |
| Moderate sedation (conscious sedation) | Purposeful response to verbal or light tactile stimulation | No intervention required | Adequate | Usually maintained |
| Deep sedation | Purposeful response to repeated or painful stimulation only | Intervention may be required | May be inadequate | Usually maintained |
| General anaesthesia | Unarousable even to painful stimulation | Intervention required | Frequently inadequate | May be impaired |
Nitrous Oxide / Oxygen Inhalation Sedation
Inhalation sedation with N₂O/O₂ is the cornerstone of paediatric dental sedation and is widely used in anxious adult patients. The procedure: pre-oxygenate with 100% O₂ via nasal hood for 1–2 minutes; introduce N₂O at 10–20% and increase in 5–10% increments at 2–3-minute intervals until the patient is relaxed and comfortable (titration to effect); typical working concentration 30–50% N₂O; administer LA and perform dental treatment; at completion, turn off N₂O and administer 100% O₂ for 5 minutes (mandatory — prevents diffusion hypoxia where N₂O leaving the blood dilutes alveolar O₂). Signs of correct sedation level: patient is relaxed and cooperative; may tingle in fingers, toes, or lips; may feel warm or light; eyes may be partially closed; responds to verbal instruction. Signs of over-sedation: patient becomes confused, uncooperative, or euphoric; nausea develops; patient does not respond normally to verbal commands — reduce concentration immediately and increase O₂.
Oral Sedation
Oral sedation involves administration of an anxiolytic drug by mouth before the dental appointment. The most commonly used agents: Temazepam (10–20mg orally 30–60 minutes before the appointment — UK): short-acting benzodiazepine; provides anxiolysis and mild sedation; patient still requires escort. Diazepam (5–10mg orally 1–2 hours before): longer-acting — residual sedation after the appointment may persist; less predictable plasma levels than temazepam. Triazolam (0.125–0.25mg — USA): ultra-short acting benzodiazepine; widely used in US dental practice for oral sedation. Limitations of oral sedation: unpredictable absorption and peak levels (patient may under-respond or, more dangerously, be more deeply sedated than anticipated); cannot titrate to effect; onset and offset cannot be controlled. A responsible adult escort is mandatory for all patients receiving oral sedation. Oral sedation alone does not reliably achieve conscious sedation consistently — it is better classified as minimal sedation to light moderate sedation.
IV Sedation
Midazolam
Monitoring required for IV midazolam sedation: continuous pulse oximetry (SpO₂ — the most important monitor); automated non-invasive blood pressure; ECG (in high-risk patients); continuous observation by a trained sedation nurse; verbal contact with the patient throughout. Discharge criteria after IV midazolam sedation: fully oriented (time, place, person); stable vital signs; able to walk in a straight line (modified Aldrete score or similar); responsible adult escort confirmed and present. The patient must be discharged with verbal and written instructions: no driving for 24 hours; no alcohol for 24 hours; no important decisions for 24 hours; emergency contact number for the practice.
Propofol
In jurisdictions where propofol is used for deep sedation by trained dental sedationists, the technique typically involves target-controlled infusion (TCI) — a computer-controlled syringe driver that maintains a pre-set plasma propofol concentration using pharmacokinetic models (Marsh or Schnider model for adults; Paedfusor model for children). This allows more precise control than manual bolus dosing. Propofol sedation requires: an anaesthetic machine capable of delivering positive pressure ventilation; an anaesthesist or dentist with appropriate anaesthetic training; full resuscitation equipment; and dedicated monitoring (capnography — end-tidal CO₂ monitoring — is mandatory for deep sedation as it detects apnoea before SpO₂ falls).
Reversal Agents
| Reversal Agent | Drug Reversed | Dose | Route | Duration | Key Concern |
|---|---|---|---|---|---|
| Flumazenil (Anexate) | All benzodiazepines (midazolam, diazepam, temazepam) | 0.2mg IV; repeat every 60s to max 1mg | IV (also IM/intranasal in some protocols) | 45–90 min | Re-sedation: flumazenil duration is SHORTER than most benzodiazepines — patient may re-sedate after initial reversal. Must not be discharged immediately after flumazenil. Contraindicated in epileptic patients on benzodiazepines (seizure risk from reversal). |
| Naloxone (Narcan) | All opioids (fentanyl, morphine, pethidine) | 0.4mg IM or IV; repeat every 2–3 min to max 10mg | IV or IM | 30–90 min | Re-narcotisation: naloxone duration is shorter than most opioids — repeated doses or infusion may be needed. Precipitates acute opioid withdrawal in opioid-dependent patients. Reversal of analgesia causes sudden severe pain → cardiovascular stress. |
General Anesthesia for Dentistry
Induction Agents
| Agent | Route | Mechanism | Advantages | Disadvantages / Dental Context |
|---|---|---|---|---|
| Propofol | IV | GABA-A + NMDA antagonism | Rapid onset; smooth induction; anti-emetic; short duration | Pain on injection; hypotension; no reversal agent; PRIS with prolonged infusion (not dental) |
| Thiopental (thiopentone) | IV | GABA-A potentiation (barbiturate) | Rapid smooth induction; anticonvulsant | No anti-emetic; no analgesia; respiratory depression; extravasation causes tissue necrosis; now largely superseded by propofol |
| Ketamine | IV or IM | NMDA receptor antagonist (dissociative) | Maintains airway reflexes better than other agents; analgesic; bronchodilator; can be given IM (paediatric) | Hallucinations and emergence delirium (particularly in adults — less in children); increases secretions (antisialagogue premedication — atropine — often given); raises ICP and IOP; cardiovascular stimulant (useful in haemodynamically compromised) |
| Sevoflurane (inhalation) | Inhaled | GABA-A potentiation + other ion channels | Non-pungent; smooth inhalational induction (paediatric — “gas induction” for needle-phobic children); maintains cardiac output well | Environmental pollution; malignant hyperthermia (rare pharmacogenetic condition — requires triggering anaesthetics avoidance) |
Maintenance of General Anaesthesia
GA may be maintained with: volatile anaesthetic agents (sevoflurane, desflurane, isoflurane — delivered via the anaesthetic machine vaporiser; carried in oxygen/air or oxygen/nitrous oxide mixture); or total intravenous anaesthesia (TIVA — propofol infusion with or without remifentanil infusion — preferred for dental procedures as it reduces PONV and does not risk pollution from volatile agents escaping around the surgical drapes). Balanced anaesthesia: the combination of an analgesic (opioid or regional anaesthetic), a hypnotic (propofol or volatile), and a muscle relaxant (if needed) — each drug at a lower dose than would be needed alone — reduces side effects.
Muscle Relaxants (Neuromuscular Blocking Agents)
Muscle relaxants abolish skeletal muscle tone (including respiratory muscles — patient requires ventilation) to facilitate endotracheal intubation and surgical access. Suxamethonium (succinylcholine): only depolarising NMBA — binds to nACh receptor and depolarises the motor end plate; causes fasciculations before paralysis; onset 30–60s (fastest of all NMBAs); duration 10–15 minutes (metabolised by plasma cholinesterase); indicated for rapid sequence induction (RSI — for patients with full stomachs requiring rapid intubation); triggers malignant hyperthermia in susceptible individuals (ABSOLUTE CONTRAINDICATION in MH). Non-depolarising NMBAs (atracurium, rocuronium, vecuronium): competitive acetylcholine antagonists at nACh receptor; no fasciculations; variable duration depending on agent; reversed by neostigmine + glycopyrrolate (anticholinesterase + antimuscarinic) or sugammadex (selective encapsulation of rocuronium/vecuronium — very rapid and reliable reversal).
Monitoring and Safety
Minimum monitoring for all dental sedation: continuous pulse oximetry (SpO₂); heart rate; automated non-invasive blood pressure; respiratory rate (observation); level of consciousness (verbal contact); trained sedation nurse in continuous attendance. Additional for IV sedation: capnography (end-tidal CO₂) is increasingly required — it detects apnoea earlier than pulse oximetry (SpO₂ may remain normal for 1–3 minutes after respiratory arrest). For deep sedation and GA: all of the above + capnography + ECG + temperature (in paediatric patients — malignant hyperthermia risk) + neuromuscular monitoring (train-of-four) when NMBAs are used. Pre-sedation assessment requirements: medical history; allergy history; current medications; previous anaesthetic history (adverse reactions, difficulty with intubation); fasting status (6 hours solids, 2 hours clear fluids for elective GA); vital signs; ASA classification; consent (informed, specific, and given in advance — not immediately before sedation).
Complications of Dental Sedation and GA
| Complication | Timing | Recognition | Management |
|---|---|---|---|
| Respiratory depression / apnoea | During sedation (midazolam, propofol, opioids) | SpO₂ fall; reduced chest rise; cyanosis; capnography flat line | Stop sedation; airway positioning; oxygen; BVM ventilation; flumazenil or naloxone (if benzodiazepine/opioid); call for help |
| Laryngospasm | During or after GA (extubation) | Stridor; paradoxical chest movement; hypoxia; complete obstruction (silent) | 100% O₂; CPAP; jaw thrust; suxamethonium 1–2mg/kg IV (breaks laryngospasm); re-intubation |
| Malignant hyperthermia | During GA (triggered by volatile agents or suxamethonium) | Rapidly rising temperature; muscle rigidity; acidosis; raised CO₂; tachycardia | Stop triggering agent immediately; call for help; dantrolene sodium 2.5mg/kg IV (SPECIFIC ANTIDOTE); cool patient; supportive care |
| Aspiration | During or after GA | Coughing; wheeze; hypoxia; X-ray changes (right lower lobe — most common site) | Head-down lateral position; suction; O₂; bronchoscopy; antibiotics (if infected aspiration) |
| Retained throat pack | Post-GA (recovery) | Airway obstruction on recovery; failure to breathe normally | Remove immediately; count throat packs at case conclusion — prevention is paramount |
| PONV | Post-operatively | Nausea, vomiting | Prophylaxis: ondansetron 4–8mg IV + dexamethasone 4–8mg IV during case; rescue: prochlorperazine, cyclizine |
Clinical Considerations
- The “rule of two” for flumazenil — the reversal duration is shorter than the drug reversed, creating a resedation risk: Flumazenil (Anexate) is a competitive benzodiazepine antagonist with a plasma half-life of approximately 45–90 minutes. Midazolam has a half-life of 1.5–2.5 hours. After flumazenil reverses apparent midazolam sedation, the patient appears alert — but as the flumazenil is cleared before the midazolam, the patient may re-sedate 60–90 minutes later. This is particularly dangerous if the patient is discharged immediately after flumazenil administration and allowed to drive home. Discharge after flumazenil: the patient must remain under observation for at least 2 hours; the responsible adult escort must be informed of the resedation risk; clear written instructions must be given. Flumazenil must not be used routinely as a “speed-up” drug to hasten discharge — its sole appropriate indication is reversal of unexpected profound sedation or respiratory depression.
- Nitrous oxide is contraindicated in the first trimester of pregnancy because it inactivates vitamin B12 — chronic recreational use (nitrous oxide abuse) causes the same irreversible B12 deficiency neuropathy: Nitrous oxide irreversibly oxidises the cobalt atom in the active site of methionine synthase (a vitamin B12-dependent enzyme) — converting it from Co(I) to Co(III), permanently inactivating it. Methionine synthase is required for: (1) converting homocysteine to methionine; (2) converting 5-methyltetrahydrofolate back to tetrahydrofolate (the active form of folate). The result: raised homocysteine; impaired DNA synthesis (folate trap); B12 deficiency syndrome — megaloblastic anaemia; subacute combined degeneration of the spinal cord (posterior column and corticospinal tract degeneration); peripheral neuropathy. In pregnancy, the first trimester is the critical period of organogenesis when folate and DNA synthesis are most crucial — N₂O exposure during this period is contraindicated. Chronic recreational N₂O abuse (“whippits” — N₂O cartridges inhaled recreationally) increasingly causes this neuropathy in young adults — an important clinical recognition topic.
- Patients with obstructive sleep apnoea (OSA) carry significantly elevated risk during sedation and general anaesthesia — the dental team must identify OSA in the medical history: OSA is characterised by recurrent upper airway collapse during sleep — the same mechanism that causes nocturnal apnoeas is exacerbated by CNS depressant drugs (benzodiazepines, opioids, propofol) which reduce upper airway tone and blunt the hypoxic respiratory response. A patient with unrecognised or poorly controlled OSA receiving IV midazolam for dental sedation has a much higher risk of developing respiratory depression and hypoxia than a non-OSA patient at equivalent doses. OSA patients should be identified from the medical history (diagnosed — treated with CPAP; or suspected — STOP-BANG questionnaire); discussion with their sleep physician if relevant; heightened monitoring during sedation (continuous SpO₂, capnography); reduced drug doses; and recovery in the sitting position (not supine).
- Ketamine is particularly valuable for paediatric dental procedures and for haemodynamically compromised patients because it maintains airway reflexes and cardiovascular function — but emergence delirium must be managed: Ketamine produces “dissociative anaesthesia” — a trancelike state with profound analgesia, amnesia, and catalepsy but with eyes open and voluntary movements preserved. The unique property of maintaining laryngeal reflexes (compared to other IV anaesthetics) makes it safer in resource-limited settings without intubation capability. It is a bronchodilator (useful for asthmatic patients). Its cardiovascular stimulant properties (increases heart rate, blood pressure, and cardiac output via sympathomimetic effects) make it useful for haemodynamically compromised patients (hypovolaemic shock) where propofol’s vasodilatory effects would be dangerous. Emergence delirium — the unpleasant hallucinations and agitation during recovery — occurs in up to 20–30% of adults (less common in children); it is attenuated by giving a small dose of midazolam or diazepam at the end of the case before emergence, or by dimming lights and minimising stimulation during recovery.
- Malignant hyperthermia is a pharmacogenetic disorder triggered by volatile anaesthetics and suxamethonium — it is a medical emergency requiring dantrolene sodium and immediate cessation of the triggering agent: MH (malignant hyperthermia) is an autosomal dominant condition (mutations in RYR1 — the ryanodine receptor type 1 on the sarcoplasmic reticulum; less commonly CACNA1S — the DHPR gene). When a susceptible patient is exposed to a triggering agent (halothane, isoflurane, sevoflurane, desflurane; or suxamethonium), uncontrolled Ca²⁺ release from the SR causes uncontrolled skeletal muscle contraction → hyperthermia (temperature can rise 1°C every 5 minutes); acidosis; rhabdomyolysis; hyperkalaemia; DIC. Recognition: unexplained rising ETCO₂ (earliest sign); rising temperature; generalised rigidity; masseter spasm after suxamethonium (masseter muscle rigidity — an early warning sign). Dantrolene sodium (2.5mg/kg IV bolus, repeated every 5 minutes to max 10mg/kg): reduces Ca²⁺ release from the SR → breaks the cycle — the SPECIFIC ANTIDOTE. All hospitals must have dantrolene available in the operating suite. Dental MH relevance: if a patient discloses a personal or family history of MH in the medical history, GA must be planned by an experienced anaesthetist using only TIVA (propofol) without volatile agents or suxamethonium, in a hospital setting equipped with dantrolene.
Common Mistakes & Misconceptions
- Misconception: “Conscious sedation means the patient is asleep.”
Correction: The defining feature of conscious sedation is that the patient is NOT asleep — they retain protective airway reflexes (gag reflex, cough reflex) and respond purposefully to verbal commands. A patient who does not respond to voice, whose airway requires support, or whose breathing is inadequate has crossed from conscious sedation into deep sedation or general anaesthesia — this requires the skill level of a trained anaesthesist to manage safely. One of the most common errors in dental sedation practice is accepting a deeply sedated patient as “just really relaxed” — the sedation continuum has been crossed and the patient is no longer in the target state. - Misconception: “Nitrous oxide is safe in all patients because it is not a ‘real’ anaesthetic.”
Correction: Nitrous oxide has specific contraindications that make it dangerous in certain patient groups: first-trimester pregnancy (B12/folate metabolism disruption during organogenesis); pneumothorax (N₂O enters the pneumothorax faster than N₂ leaves, expanding it and worsening the tension pneumothorax); recent tympanoplasty or middle ear surgery (N₂O expands the middle ear air space, potentially disrupting the tympanic membrane repair); bowel obstruction (N₂O expands intestinal gas → perforation risk). Additionally, chronic or acute high-dose exposure causes B12-deficiency neuropathy — this has become clinically significant as recreational N₂O abuse has risen sharply in young adults. “Harmless laughing gas” is a misleading description in both contexts. - Misconception: “The reversal agent (flumazenil) can be given and then the patient can be discharged quickly.”
Correction: Flumazenil is a short-acting competitive antagonist — its effect wears off before the benzodiazepine it reversed, creating a real risk of resedation after apparent recovery. It is not a “get-out-of-jail-free” drug to hasten discharge. Standard post-flumazenil observation period: 2 hours minimum. The patient requires a responsible adult escort regardless of whether flumazenil was given. Written and verbal post-sedation instructions must be given. The patient must not drive for 24 hours — flumazenil does not make the patient fit to drive; it temporarily reverses the pharmacodynamic effect while the benzodiazepine is still in the body. - Misconception: “Ketamine is dangerous because it stops breathing.”
Correction: Among the IV anaesthetic induction agents, ketamine is uniquely protective of the airway — it maintains laryngeal reflexes better than any other IV agent and rarely causes respiratory depression at clinical doses. This makes it particularly valuable in emergency settings, resource-limited environments, and paediatric cases. Its main disadvantages are emergence delirium in adults and increased oral secretions (which are managed with atropine premedication). The drugs that commonly cause respiratory depression in dental sedation are benzodiazepines (midazolam) and opioids — not ketamine. - Misconception: “The throat pack placed by the anaesthetist will be removed automatically at the end of the case.”
Correction: Retained throat packs are a recognised cause of airway obstruction and death following dental general anaesthesia. Throat pack retention occurs because: the pack is not formally counted in the surgical count; it is obscured by the surgical drapes; it swells with absorbed blood and blends with pharyngeal tissues. Prevention requires: formal documentation of throat pack insertion in the anaesthetic record; a radio-opaque thread in the pack (visible on X-ray); and formal verification of throat pack removal before extubation — confirmed by direct visualisation, and documented. The anaesthetic team and surgical team both share responsibility for this check.
Related Topics
References & Sources
- Intercollegiate Advisory Committee on Sedation in Dentistry (IACSD) (2015). Standards for Conscious Sedation in the Provision of Dental Care. Faculty of Dental Surgery, Royal College of Surgeons of England. [UK standards for dental conscious sedation — competencies, monitoring, facilities]
- American Academy of Pediatric Dentistry (2019). Guidelines for Monitoring and Management of Pediatric Patients Before, During, and After Sedation. AAPD. [US paediatric sedation guidelines — sedation continuum, monitoring, drugs]
- American Society of Anesthesiologists (2018). Continuum of Depth of Sedation: Definition of General Anesthesia and Levels of Sedation/Analgesia. asahq.org. [The standard US classification of sedation levels]
- Yagiela JA, Dowd FJ, Johnson BS, Mariotti AJ, Neidle EA (2011). Pharmacology and Therapeutics for Dentistry, 6th ed. Mosby. [Dental pharmacology — sedation agents, mechanisms, interactions]
- Eger EI (2001). New inhaled anesthetics. Anesthesiology, 80(4):906–922. [Volatile anaesthetic mechanisms and properties]
- Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K (2015). Malignant hyperthermia: a review. Orphanet Journal of Rare Diseases, 10:93. [MH pathophysiology, RYR1 genetics, dantrolene treatment]
- Pani SC, Moody D, Durantaye M (2010). Sedation for dental care in paediatric patients — a review of the literature. International Journal of Paediatric Dentistry. [N₂O and oral sedation evidence base for children]
- Schelling G, Stoll C, Haller M, et al. (1998). PTSD and health-related quality of life in survivors of the acute respiratory distress syndrome. [Sedation awareness and psychological impact of inadequate sedation — ICU context but relevant to dental GA recovery principles]
Summary
Dental sedation covers a continuum from minimal anxiolysis to general anaesthesia. The practitioner must be capable of rescuing from one level deeper than intended. Nitrous oxide/oxygen is the safest technique — complete recovery before the patient leaves, no escort needed beyond the appointment (though recommended). Contraindications: first trimester pregnancy, pneumothorax, bowel obstruction, middle ear surgery. Midazolam IV is the standard drug for IV conscious sedation — anterograde amnesia; titrated to Verril’s sign; reversible with flumazenil (resedation risk — observe 2 hours after reversal). Propofol is used for deep sedation/GA induction — not reversible; respiratory depression common; requires anaesthetic-trained personnel. GA for dentistry: shared airway; nasotracheal tube preferred; throat pack must be formally documented and removed before extubation; PONV prophylaxis with ondansetron + dexamethasone. Malignant hyperthermia: triggered by volatile agents and suxamethonium; dantrolene sodium is the specific antidote.
Key Takeaways
- Sedation continuum: Minimal → Moderate (dental target: purposeful response + intact airway reflexes) → Deep → GA. Must rescue from one level deeper. Transition can happen unexpectedly.
- Nitrous oxide: Safest technique; complete recovery before leaving; mandatory O₂ flush 5 min post-procedure (diffusion hypoxia); contraindicated in 1st trimester, pneumothorax, middle ear surgery, bowel obstruction; chronic exposure → B12 neuropathy.
- Midazolam IV: GABA-A agonist; anterograde amnesia; Verril’s sign = sedation endpoint (ptosis); flumazenil reversal — observe 2h (resedation risk); escort + no driving 24h mandatory.
- GA dentistry: Nasotracheal intubation preferred; throat pack = formal count, document insertion AND removal; PONV prophylaxis; intraoperative LA for postoperative analgesia; fasting 6h solid / 2h clear fluids.
- Malignant hyperthermia: RYR1 mutation; triggered by volatile agents + suxamethonium; early sign = rising ETCO₂ + rigidity + hyperthermia; treatment = stop trigger + dantrolene sodium 2.5mg/kg IV.
About the Author
